# Effects Tables

## Outcome

### Reduction of LDL-C level in blood

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Statins** | **Ezetimibe (Combined)** | **Ezetimibe (Mono)** | **Alirocumab (Combined)** | **Alirocumab (Mono)** | **Evolocumab** |
| **Reduction of LDL** | NA | 33% -45’%[35] | 14 % [35] | 59,9%-80% from Baseline [36]  62% [37]   * 62% | 77% [38] | 9% (30) [39] (Pat. without apheresis) |

### Reduction of cardiovascular events

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Statins** | **Ezetimibe (Combined)** | **Ezetimibe (Mono)** | **Alirocumab (Combined)** | **Alirocumab (Mono)** | **Evolocumab** |
| **Stroke** | ‘-18%[40] |  |  |  |  |  |

## Adverse Events

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Statins** | **Ezetimibe (Combined)** | **Ezetimibe (Mono)** | **Alirocumab (Combined)** | **Alirocumab (Mono)** | **Evolocumab** |
| **Infections** |  |  |  | 55,2% [36] |  |  |
| **Allergic reactions** |  |  |  | 10,1%  (Placebo=9,5%) [37] |  |  |
| **Diarrhea** | 0% [39] |  | 3,9% [41] | 29,3% [36]  3,9% [42] | 11,5%[41] | 6% [39] |
| **Nausea** | 13% [39] |  | 5,9% [41] | 2,5% [42] | 5,8%[41] | 0% [39] |
| **Influenza** | 0% [39] |  | 5,9% [41] |  | 11,5%[41] | 9% [39] |
| **Arthralgia** |  |  | 3,9% [41] |  | 5,8%[41] |  |
| **Head ache** |  |  | 3,9% [41] |  | 5,8%[41] |  |
| **Skin lesions at the injection site** | n.a. | 0,8% [38] | 3,9% [41] | 34,5 %[36]  2,5% [38]  5,9% (Placebo=4,2%) [37] | 1,9%%[41] |  |
| **General skin changes** |  |  |  | 15,5% [36] |  |  |
| **Nasopharyngitis** | 0% [39] |  | 15, 7% [41] |  | 23,1%[41] | 6% [39] |
| **Inflammation of the upper respiratory tract** | 6% [39] | 5,8% [38] | 9,8% [41] | 6,5%[38] | 3,8%[41] | 9% [39] |
| **Respiratory, thoracic and mediastinal disorders** |  |  |  | 17,2% [36] |  |  |
| **Back pain** |  |  | 5,9% [41] |  | 1,9%[41] |  |
| **Myalgia** |  | 0% [39]  5,0% [38] | 9,8% [41] | 4,4% [38]  5,4% (Placebo= 2,9%) [37] | 3,8% [41] | 3% [39] |
| **Dizziness** |  | 5,4%[38] | 5,9% [41] | 4,8%[38] | 1,9%[41] |  |
| **Nervouse system disorders/**  **Nerocognitive disorder** |  | 1,2% [38] |  | 29,3% [36]  0,8% [38]  1,2% (Placebo=0,5%) [37] |  |  |
| **Psychiatric disorders** |  |  |  | 12,1% [36] |  |  |

## Mode of Administration

|  |  |
| --- | --- |
|  | **Alirocumab (Mono)** |
| **Mode of Administration** | 1\* every 14 days, Subcutaneous injection with auto-injector (self-application) (75mg)[41] |